Merck & Co. (MRK) — Stockfinity

← Tillbaka till ranking

Merck & Co.

MRK SP500 Healthcare

AVVAKTA

54/100

Rank 231 av 500

130.20 USD +0.32% idag Live

Kursutveckling (180 dagar)

MRK OMX30 (normaliserad)

Kursutveckling vs OMX30

1 dag

+0.32%

-0.1% vs OMX30

1 vecka

-0.66%

-2.1% vs OMX30

1 månad

+1.32%

-0.6% vs OMX30

3 månader

+19.19%

+12.9% vs OMX30

6 månader

+22.12%

+14.4% vs OMX30

Fundamentala nyckeltal

P/E (trailing) 36.7

P/E (forward) 13.5

PEG 12.06

P/B 7.0

P/S 4.9

EV/EBITDA 12.4

Oms. tillväxt +4.9%

Vinstmarginal 13.6%

Rörelsemarginal 38.6%

ROE 18.9%

ROA 12.6%

Skuld/EK 107%

Likviditetskvot 1.30

Direktavkastning 2.6%

Börsvärde 321.6B

Analytikerkonsensus

BUY Riktkurs: 135 USD (26 analytiker)

AI-analys

Teknisk 10.6

Sentiment 0.0

Total 53.7

Risk MEDEL

Kort sikt (3 månader)

54/100

Baserat enbart på tekniska signaler.

Lång sikt (3 år)

52/100

Baserat enbart på sentiment, inga fundamenta tillgängliga.

Övergripande motivering

Bortsållad av Haiku-förfilter — visas inte i topp-listan men sparas för historik.

Senaste nyheter

yahoo_finance 2026-07-30

Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?

MRK heads into Q2 earnings with acquisition costs, Keytruda strength and Gardasil challenges likely to shape results. Is the stock still worth holding?

yahoo_finance 2026-07-30

Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?

MRK heads into Q2 earnings with acquisition costs, Keytruda strength and Gardasil challenges likely to shape results. Is the stock still worth holding?

Visa på Avanza Yahoo Finance